20 November 2026 Punjab Khabarnama Bureau : A promising new development in cancer research has raised fresh hopes for patients battling pancreatic cancer after an experimental daily pill, daraxonrasib, showed encouraging results when combined with chemotherapy. The treatment helped shrink or eliminate tumours in several patients during an early clinical trial, offering new possibilities for people suffering from one of the deadliest forms of cancer.
The study involved 61 patients diagnosed with advanced pancreatic cancer that had spread to other parts of the body. Researchers found that the combination of daraxonrasib and chemotherapy produced significant responses, with tumours stopping their growth in approximately 90 per cent of participants.
According to the reported findings, more than 60 per cent of patients experienced a reduction in tumour size or the complete disappearance of detectable tumours. In approximately 8 per cent of participants, cancer became undetectable through CT scans, meaning doctors could no longer identify visible signs of the disease through the imaging tests.
These results have attracted considerable attention from cancer researchers and medical experts because pancreatic cancer has remained particularly difficult to treat. Although existing treatments, including chemotherapy, can sometimes slow the disease, patients with advanced pancreatic cancer often experience a return of tumour growth.
Daraxonrasib Offers New Possibilities in Cancer Treatment
Daraxonrasib is a targeted cancer medicine designed to block signals produced by abnormal RAS proteins, particularly mutations involving KRAS. These mutations play a significant role in encouraging cancer cells to grow and multiply.
KRAS mutations are found in the majority of pancreatic cancer cases and have historically been considered extremely difficult to target with medicines. Scientists have spent decades searching for effective ways to block these proteins and prevent them from driving tumour development.
The new treatment aims to interrupt these cancer-related signals, potentially slowing or stopping the growth of malignant cells. When administered alongside chemotherapy, daraxonrasib may help produce stronger responses than traditional treatment approaches alone.
Researchers believe that targeting the biological mechanisms responsible for tumour growth could represent an important step towards developing more effective treatments for pancreatic cancer.
Trial Results Show Significant Tumour Responses
The early clinical trial produced several encouraging findings. Researchers reported that approximately 90 per cent of the 61 participants experienced disease control, meaning their tumours stopped growing or did not show further progression during the measured period.
More than 60 per cent of patients experienced tumour shrinkage or disappearance, while around one in 12 participants had no detectable cancer on CT scans.
The median follow-up period was approximately 18 months, allowing researchers to observe how patients responded to the treatment over time.
Experts involved in the research have described the findings as highly encouraging, particularly because advanced pancreatic cancer is generally associated with poor treatment outcomes.
Dr Wungki Park of Memorial Sloan Kettering Cancer Center, who was involved in the trial, said the treatment was producing deeper tumour responses and a significant improvement in the duration of disease control. Researchers hope these developments could eventually translate into longer survival for patients.
However, specialists have emphasised that the findings are still preliminary and should be interpreted carefully.
Why Pancreatic Cancer Is So Difficult to Treat
Pancreatic cancer develops in the pancreas, an organ located behind the stomach that plays an important role in digestion and blood sugar regulation.
One of the biggest challenges associated with this disease is that it often develops without obvious symptoms during its early stages. As a result, many patients are diagnosed only after the cancer has spread to nearby tissues or other organs.
Common warning signs can include unexplained weight loss, abdominal or back pain, jaundice, tiredness, digestive problems and changes in urine or stool colour.
By the time the disease reaches an advanced stage, treatment options can become limited. Surgery may not be possible for patients whose cancer has spread, while chemotherapy often focuses on slowing tumour growth and managing symptoms.
According to Cancer Research UK figures cited in reports, approximately 11,500 people are diagnosed with pancreatic cancer in Britain each year, while around 10,200 die from the disease.
The poor survival outcomes have made the development of new treatment options an important priority for cancer researchers worldwide.
Experts Urge Caution Despite Encouraging Findings
Despite the excitement surrounding daraxonrasib, medical experts have warned that the treatment should not yet be considered a cure for pancreatic cancer.
The disappearance of visible tumours on medical scans does not necessarily mean that every cancer cell has been eliminated from the body. Microscopic cancer cells may remain and could potentially cause the disease to return later.
Researchers also need more time to understand how long the treatment can control tumour growth and whether it can significantly improve overall survival.
Cancer Research UK has described the findings as a major development for pancreatic cancer research while highlighting the importance of additional clinical studies.
Experts have also stressed that larger trials are required to establish the treatment’s long-term effectiveness, safety and suitability for different groups of patients.
Potential Impact Beyond Pancreatic Cancer
The research could have implications beyond pancreatic cancer because RAS-related mutations are also found in several other types of cancer, including certain lung and ovarian cancers.
Scientists hope that advances in targeting these mutations could support the development of new treatments for patients with other difficult-to-treat diseases.
However, further research will be necessary to determine whether daraxonrasib can provide similar benefits in other cancers.
For now, the early findings represent a significant source of optimism for pancreatic cancer research. While the treatment has not established a cure, the possibility of shrinking tumours, controlling disease progression and extending patients’ lives offers fresh hope.
Researchers will continue monitoring patients and studying the treatment to determine whether these promising early results can be confirmed in larger clinical trials. For patients and families affected by pancreatic cancer, the findings offer encouragement in the ongoing search for more effective cancer treatments.
